Taiho Pharmaceutical Company

Araris Biotech AG is a biotechnology start-up based in Zurich, Switzerland, founded in 2019. The company specializes in developing antibody-drug conjugate (ADC) linker technology aimed at enhancing chemotherapy by delivering chemotherapeutic agents directly to targeted antibodies. This innovative platform allows for the rapid production of high-quality ADCs without the need for extensive engineering of antibodies or cell lines, enabling the use of readily available antibodies. The site-specific conjugation process facilitates swift manufacturing and reliable quality control, supporting the creation of safe and potent drugs for various diseases. Araris Biotech's technology is protected by two patents, underscoring its commitment to advancing cancer treatment through improved safety and tolerability for patients.

StapleBio is a biotechnology company focused on the research and development of pharmaceuticals utilizing advanced staple nucleic acid technology. The company has developed a unique platform that selectively hybridizes with target messenger ribonucleic acid (mRNA) to create an artificial ribonucleic acid higher-order structure, known as RNA G-quadruplex (RGq). This innovative approach allows for the modulation of protein expression levels without relying on enzymatic bioprocesses commonly used in RNA interference or antisense technologies. By enabling the introduction of artificial nucleic acids into various sequences, StapleBio's technology has significant potential applications in detecting and treating conditions such as cancer, neurological disorders, autoimmune diseases, and viral infections.

Cullinan Pearl, a subsidiary of Cullinan Oncology, focuses on developing innovative cancer therapies, specifically targeting Epidermal Growth Factor Receptor (EGFR) exon 20 mutations through its orally available tyrosine kinase inhibitor. The company is part of a broader strategy to create a diverse portfolio of oncology therapeutics, relying on a combination of internal research and collaborative efforts with academic institutions and pharmaceutical companies. This approach allows Cullinan Pearl to efficiently advance its drug development programs, with a commitment to rapidly discontinue any projects that show limited potential based on early research findings. As part of its ongoing initiatives, Cullinan Pearl collaborates with Cullinan Oncology to support the development and commercialization of its therapies.

AuB, Inc., founded in 2015 and based in Chuo, Japan, focuses on researching and developing supplements, foods, and beverages aimed at enhancing the intestinal environment of athletes. The company specializes in intestinal microflora analysis, which is integral to improving athletic performance and maintaining overall human health. AuB offers a range of health supplements and cosmetics that are informed by microbiome research and stool sample analysis of athletes. Additionally, the company provides dietary improvement services tailored to the results of an athlete's intestinal flora data, enabling both consumers and athletes to optimize their health and performance.

Quentis Therapeutics, Inc. is a biotechnology company founded in 2016 and based in New York, specializing in the development of cancer immunotherapies. The company's innovative therapeutics focus on modulating endoplasmic reticulum (ER) stress response pathways within the tumor microenvironment. By targeting these pathways, Quentis Therapeutics aims to enhance the immune system's ability to combat cancer, thereby providing patients with access to novel treatment options. The company's approach seeks to translate cutting-edge biological insights into effective therapeutic strategies that can improve anti-tumor immunity.